Generic Name and Formulations:
Insulin aspart (recombinant) 100 Units/mL; soln for SC inj, continuous subcutaneous insulin infusion (CSII), IV infusion; contains zinc, m-cresol.
For SC inj, CSII, or IV infusion: see literature. Onset approx ≤15 minutes, peak approx 1–3 hours, duration approx 3–5 hours.
<2yrs: not recommended. 2–4yrs: use SC inj only. ≥4yrs: may use SC inj or CSII: see literature. Onset approx ≤15 minutes, peak approx 1–3 hours, duration approx 3–5 hours.
During episodes of hypoglycemia.
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. CSII: Do not mix with other insulins or diluent when pump is used.
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.
Vials (10mL)—1; FlexPen (3mL prefilled syringe)—5; PenFill (3mL cartridges)—5; NovoPen Echo (inj device, uses PenFill cartridges)—1